Xencor to Participate in Upcoming Investor Conferences
MONROVIA, Calif.--(BUSINESS WIRE)--Apr 1, 2019--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced that company management will participate in two upcoming conferences:
Annual IO Cell Therapy Summit
Date: Friday, April 5, 2019
Location: Boston, MA
Annual Needham Healthcare Conference
Date: Tuesday, April 9, 2019
Presentation Time: 2:10 p.m. ET
Location: New York, NY
A live webcast of the Needham Healthcare Conference presentation will be available under “Events & Presentations” in the Investors section of the Company’s website located at https://investors.xencor.com/events.cfm. A replay of the event will be posted on the Xencor website approximately one hour after the live event and will be available for 90 days following the event.
About Xencor, Inc.
Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases. Currently, 12 candidates engineered with Xencor’s XmAb ® technology are in clinical development internally and with partners. Xencor’s XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190401005858/en/
CONTACT: Charles Liles
Jason I. Spark
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA MASSACHUSETTS NEW YORK
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY ONCOLOGY PHARMACEUTICAL
SOURCE: Xencor, Inc.
Copyright Business Wire 2019.
PUB: 04/01/2019 04:05 PM/DISC: 04/01/2019 04:05 PM